Business Wire

Ricardo Commissioned to Define a Single Harmonised European Life Cycle Assessment Standard for Zero Emission Vehicles and Batteries

15.2.2023 03:01:00 EET | Business Wire | Press release

Share

Ricardo, a global strategic environmental and engineering consulting company, has commenced a European Union-funded project to develop a baseline for a European-wide commonly accepted and applied single life cycle assessment (LCA) approach for zero emission vehicles (ZEV) and batteries based on evidence and real-world data. This initiative is a Coordination and Support Action supported under the Horizon Europe Framework Programme and has also received funding from UK Research and Innovation (UKRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005551/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Electric car and truck charging (Photo: Business Wire)

Currently, there is no agreed European or international standard on vehicle life cycle assessment, although there are a number of standards in draft or being developed for electric vehicle (EV) batteries. Defining a single, harmonised life cycle assessment approach for vehicles and batteries is key to providing transparency and comparability of impacts from these products. This will help to achieve Green Deal targets, making Europe the first digitally enabled circular, climate-neutral and sustainable economy. Harmonised standards will facilitate industry, mobility providers and planners to develop sustainable road transport products that are optimised to combat climate change. Ricardo is on the core team of the collaborative TranSensus LCA consortium – jointly coordinated by the Fraunhofer Institute for Structural Durability and System Reliability LBF and the Fraunhofer-Institution of Surface Engineering and Thin Films IST– which comprises 44 stakeholders from industry and research along the full value chain of zero emission vehicles and batteries including: research institutions, vehicle and battery manufacturers, the supply industry, energy providers and recyclers.

Nikolas Hill, Head of Vehicle Technologies and Fuels in Ricardo’s Sustainable Transport team said: “The major report on life cycle impacts of road vehicles that Ricardo undertook for the European Commission in 2020 highlighted the importance of life cycle assessment in sustainable product and business development, but also the challenges for its application. In particular, efforts fully to use and realise the benefits from life cycle assessment approaches by the transport sector are being hampered because there is not an official European standard for vehicle LCA. This is largely because of a lack of a consistent, fair framework or harmonised methodology, plus limitations in accessing and managing real-world data and applying consistent modelling. Through our work with our industry and research partners on this project, Ricardo policy, strategy and technology experts will help to deliver a standard, trustworthy and consistent assessment of full vehicular environmental footprints, to support organisations across the transport value chain progress their objective of achieving climate neutrality.”

Ricardo’s 2020 report for the European Commission, DG Climate Action: Determining the environmental impacts of conventionally and alternatively fuelled vehicles through LCA was the broadest and most comprehensive study of its kind to date. The report assessed the life cycle impacts of 65 different European light- and heavy-duty vehicle types and powertrain combinations. It considered the production of 60 fuel chains for conventional and alternative fuels as well as 14 different forms of electricity generation, the impacts of vehicle (and battery) manufacturing, and vehicle use and maintenance including different ‘end of life’ scenarios. The report also highlighted the positive impact of existing European Union policy in directly supporting the move to a more circular economy and the initiatives aimed at developing a sustainable value chain for hybrid and fully electric vehicles and their batteries in driving down industrial emissions and improving resource efficiency.

Ends

Notes to editors:

TranSensus LCA is funded by the European Union under the Grant Agreement #101056715. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye